STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it presented promising data from its ...

Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...

Dizal has submitted sunvozertinib’s new drug application (NDA) to the US Food and Drug Administration (FDA) aiming to secure approval for treating locally advanced or metastatic non-small cell lung ...

and BioVie’s Triolex (bezisterim), an inhibitor of inflammatory mediators, which has a Phase III trial planned in the US due to its neuroprotective potential. Palmer adds: “26% of the pipeline DMTs in ...

Mind Medicine’s share price has responded very strongly to Q3 update that contained very little new information. Read why I ...

Heart failure sounds scary - because it is. But here's the thing: millions of Americans are walking around right now with a ...

InflaRx cofounder and CEO Niels Riedemann, M.D. shares the overarching pillars that have shaped his career as a physician, ...

It may result from autoimmunity or as a side effect to certain pharmaceuticals (including checkpoint inhibitors), but is most commonly caused by viral infections ... This clearly highlights the unique ...

October 2024, saw significant FDA actions and clinical trial updates that shaped cancer treatment progress ... Cancers Symposium® will focus on treatment strategies in early-stage lung cancers, ...

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

Detailed price information for Mink Therapeutics Inc (INKT-Q) from The Globe and Mail including charting and trades.